Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Tuesday, May 7, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has announced that its ECUR-506 program has received FDA Fast Track Designation. This designation is aimed at expediting the development of therapies for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency. The company utilizes its proprietary ARCUS platform for advanced gene editing therapies.
Price reaction · baseline $10.66 (2024-05-06 close) · hit pre-market · 2 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
-0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA Fast Track Designation received for ECUR-506.
  • Potential for improved treatment of Neonatal Onset OTC Deficiency.
  • Highlights Precision BioSciences' innovative gene editing technology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–May 7, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision,

Frequently Asked Questions

What is ECUR-506?

ECUR-506 is a gene therapy program developed by Precision BioSciences for treating Neonatal Onset OTC Deficiency.

What does FDA Fast Track Designation mean?

FDA Fast Track Designation is a process to expedite the development and review of drugs that treat serious conditions.

How does the ARCUS platform work?

The ARCUS platform is a proprietary gene editing technology used by Precision BioSciences for in vivo therapies.

What condition does ECUR-506 target?

ECUR-506 targets Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences ECUR-506 FDA Fast Track OTC Deficiency gene editing
Last updated: May 7, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →